Oppenheimer analyst Steven Lichtman downgrades Medtronic (NYSE:MDT) from Outperform to Perform and lowers the price target from $106 to $85.
Oppenheimer Downgrades Medtronic to Perform, Lowers Price Target to $85
Oppenheimer analyst Steven Lichtman downgrades Medtronic (NYSE:MDT) from Outperform to Perform and lowers the price target from $106 to $85.
Related Posts
Baudax Bio Touts Additional Positive Data From Nerve Blocker In Surgery Patients
Baudax Bio Inc (NASDAQ: BXRX) announced additional results from its Phase 2 trial of BX1000 for neuromuscular blockade (NMB) in patients
In-Depth Examination Of 4 Analyst Recommendations For Staar Surgical
Throughout the last three months, 4 analysts have evaluated Staar Surgical (NASDAQ:STAA), offering a diverse set of opinions…
Meta’s AI-Powered Future At Connect 2023, Analysts Show Positive Reception
On Wednesday, Meta Platforms Inc (NASDAQ: META) Chief Executive Mark Zuckerberg rolled out new AI products for consumers, including AI Assistants (Meta AI), image editing and generation tools (Emu, Backdrop, Re-Style), and a new platform for developing customized AI assistants (AI Studio) and an&n